Literature DB >> 26934471

Tumour angiogenesis-Origin of blood vessels.

S Krishna Priya1, R P Nagare1, V S Sneha1, C Sidhanth1, S Bindhya1, P Manasa1, T S Ganesan1.   

Abstract

The conventional view of tumour vascularization is that tumours acquire their blood supply from neighbouring normal stroma. Additional methods of tumour vascularization such as intussusceptive angiogenesis, vasculogenic mimicry, vessel co-option and vasculogenesis have been demonstrated to occur. However, the origin of the endothelial cells and pericytes in the tumour vasculature is not fully understood. Their origin from malignant cells has been shown indirectly in lymphoma and neuroblastoma by immuno-FISH experiments. It is now evident that tumours arise from a small population of cells called cancer stem cells (CSCs) or tumour initiating cells. Recent data suggest that a proportion of tumour endothelial cells arise from cancer stem cells in glioblastoma. This was demonstrated both in vitro and in vivo. The analysis of chromosomal abnormalities in endothelial cells showed identical genetic changes to those identified in tumour cells. However, another report contradicted these results from the earlier studies in glioblastoma and had shown that CSCs give rise to pericytes and not endothelial cells. The main thrust of this review is the critical analysis of the conflicting data from different studies and the remaining questions in this field of research. The mechanism by which this phenomenon occurs is also discussed in detail. The transdifferentiation of CSCs to endothelial cells/pericytes has many implications in the progression and metastasis of the tumours and hence it would be a novel target for antiangiogenic therapy.
© 2016 UICC.

Entities:  

Keywords:  cancer stem cells; endothelial cells; pericytes; tumour angiogenesis

Mesh:

Substances:

Year:  2016        PMID: 26934471     DOI: 10.1002/ijc.30067

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

1.  miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1.

Authors:  Jian Wang; Huaqiang Liu; Lin Tian; Fachen Wang; Liangbo Han; Wei Zhang; Yun-An Bai
Journal:  Horm Cancer       Date:  2016-11-28       Impact factor: 3.869

2.  ETS transcription factors Etv2 and Fli1b are required for tumor angiogenesis.

Authors:  Kristina Baltrunaite; Michael P Craig; Sharina Palencia Desai; Praneet Chaturvedi; Ram Naresh Pandey; Rashmi S Hegde; Saulius Sumanas
Journal:  Angiogenesis       Date:  2017-01-20       Impact factor: 9.596

3.  MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.

Authors:  Wenjiong Hao; Wei Luo; Mangmang Bai; Jian Li; Xiaobin Bai; Jie Guo; Jinsong Wu; Maode Wang
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

Review 4.  Long noncoding RNAs, emerging and versatile regulators of tumor-induced angiogenesis.

Authors:  Jing Zhao; Li Li; Zhong-Ying Han; Zheng-Xin Wang; Lun-Xiu Qin
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

Review 5.  Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry.

Authors:  Elena Andreucci; Silvia Peppicelli; Jessica Ruzzolini; Francesca Bianchini; Lido Calorini
Journal:  Cancer Metastasis Rev       Date:  2022-10-13       Impact factor: 9.237

6.  Discovery and Development of Tumor Angiogenesis Assays.

Authors:  Gianfranco Natale; Guido Bocci
Journal:  Methods Mol Biol       Date:  2023

Review 7.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

8.  Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.

Authors:  S Krishna Priya; Kishore Kumar; K R Hiran; M R Bindhu; Rohit P Nagare; D K Vijaykumar; T S Ganesan
Journal:  Int J Clin Oncol       Date:  2016-08-27       Impact factor: 3.402

9.  Investigation of the Mechanism of Traditional Chinese Medicines in Angiogenesis through Network Pharmacology and Data Mining.

Authors:  Wingyan Yun; Wenchao Dan; Jinlei Liu; Xinyuan Guo; Min Li; Qingyong He
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-28       Impact factor: 2.629

10.  BPIFB1 inhibits vasculogenic mimicry via downregulation of GLUT1-mediated H3K27 acetylation in nasopharyngeal carcinoma.

Authors:  Xianjie Jiang; Xiangying Deng; Jie Wang; Yongzhen Mo; Lei Shi; Fang Wei; Shanshan Zhang; Zhaojian Gong; Yi He; Fang Xiong; Yumin Wang; Can Guo; Bo Xiang; Ming Zhou; Qianjin Liao; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  Oncogene       Date:  2021-11-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.